Synopsis: James McArthur is the CEO of PepGen, a biotech company creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic diseases, with an initial focus on neuromuscular diseases. James talks about his experience on the venture capital side and how that has influenced his management style and overall approach to company building. He shares his advice to others who may be interested in pursuing a leadership role at their company. He discusses drug development in the rare disease space and what motivates him and his team. Finally, he talks about some of the challenges involved in running a rare disease company. Biography: James McArthur currently serves as Chief Executive Officer of PepGen and serves on the company’s Board of Directors. James has 25+ years of industry experience, has cofounded 5 biotechnology companies, 3 of which were acquired, and has served as a Director of two companies through successful initial public offerings. He was founding CEO of Imara, a public company developing therapies for sickle cell disease and beta-thalassemia, co-founder and President of R&D of Cydan, a rare disease accelerator, and founding CSO of Synovex/Adheron, a rheumatology therapy company acquired by Roche. Prior to these companies, James held senior research leadership roles in several pioneering gene and stem cell therapy companies. He was a Venture Partner at RA Capital and an entrepreneur in residence at HealthCare Ventures. James was previously a post-doctoral fellow at MIT and UC Berkeley working with Drs. David Raulet and Nobel Laureate James Allison, before which he received his PhD in molecular oncology and BSc in biochemistry from McGill University in Montreal.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related